Phoenix, Arizona: bioSyntagma has been named a finalist for the competitive Katerva Awards, which recognize disruptive innovations in global sustainability. This comes after bioSyntagma’s recent debut of their mPrint Mind™, an artificial intelligence for screening cancer patients.
The bioSyntagma Team
“We are delighted by the news and encouraged that such an innovative group recognizes the value of creating a sustainable healthcare system,” said David Richardson, CEO of bioSyntagma. Katerva scours the globe to identify the most promising, high-impact innovations that will make the world a better place and move society closer to the 17 Sustainable Development Goals set forth by the United Nations.
Rising costs and growing numbers of diagnostic tests on the market are a huge financial burden, especially considering that most cancer patients are developing drug resistance to their treatments.
“Tackling drug resistance is a crucial step in enabling personalized medicine but also in reducing costs and democratizing access,” said Colleen Ziegler, Director of Operations at bioSyntagma. “This is why we have invested so much in AI. It will change the entire landscape.”
See the full list of finalists for each sustainability category at: https://katerva.net/news/10-announcing-the-finalists-of-the-2019-katerva-awards
About bioSyntagma
bioSyntagma is a precision medicine company that enables advanced biomarker discovery and patient screening. Its suite of AI-enabled technologies enables comprehensive mapping of cancer patient
biopsies (spatial, multi-omic) so that patients can be matched with relevant therapies and provided recommendations to avoid acquiring drug resistance. bioSyntagma serves the needs of clinicians, academic researchers, and drug developers to advance the implementation of precision medicine for cancer treatment. The founders are from Arizona State University and members of the Center for Entrepreneurial Innovation.